Every 10-Q that Aimei Health Technology Co., Ltd (AFJK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AFJK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AFJK filings page.
Aimei Health Technology Co., Ltd., a SPAC focused on healthcare innovation, reported a small net loss of $37,704 for the six months ended June 30, 2026, as general, administrative and operational costs of $254,332 exceeded $216,628 of interest income on cash held in its trust account.
Assets totaled $12.53 million, including $12.49 million in the Trust Account and only $1,466 of operating cash, alongside a working capital deficit of $3.79 million and $2.20 million of related-party extension loans. As of June 30, 2026, 1,040,332 public shares were classified as redeemable at $12.00 per share, with an additional 2,126,000 non-redeemable ordinary shares outstanding.
The company terminated its previously agreed Business Combination Agreement with United Hydrogen on July 7, 2026, so that transaction will not close, and it continues to search for a new target. Management disclosed substantial doubt about the ability to continue as a going concern if no business combination is completed by the extended deadline, and also reported a material weakness in internal controls related to inadequate segregation of duties and insufficient written procedures.
Aimei Health Technology Co., Ltd. reported Q1 2026 results as a SPAC still seeking to close its initial business combination. For the three months ended March 31, 2026, it recorded net income of $45,440, driven by $107,424 of interest on cash held in the Trust Account and offset by $61,984 of general, administrative and operational costs.
As of March 31, 2026, cash in the operating account was $18,516 with $12,276,196 held in the Trust Account and a working capital deficit of about $3,499,377. A total of 1,040,332 ordinary shares were classified as subject to possible redemption at a redemption value of $11.80 per share, alongside 2,126,000 non-redeemable ordinary shares.
The company has a pending Business Combination Agreement with United Hydrogen and notes that completion remains subject to conditions, including China Securities Regulatory Commission approval. Management discloses substantial doubt about its ability to continue as a going concern if a business combination is not completed by the July 6, 2026 combination deadline.
Aimei Health Technology Co., Ltd. (AFJK) filed its quarterly report for the period ended September 30, 2025, showing it remains a pre-revenue SPAC earning income from its trust investments. The company reported net income of $352,019 for the quarter and $961,651 for the nine months, driven by $482,171 and $1,546,821 of interest on cash held in the trust account, partially offset by formation and operating costs. As of September 30, 2025, Aimei held $45,443,570 in its trust account and had a working capital deficit of about $2.75 million, with only $2,979 of cash outside the trust. During February 2025, shareholders redeemed 2,904,267 shares for approximately $31.27 million, reducing redeemable shares to 3,995,733. The company has a signed business combination agreement with United Hydrogen, which shareholders later approved, and has repeatedly extended its deadline to complete the merger to December 6, 2025 using unsecured promissory notes from its sponsor and United Hydrogen. Management notes that failure to close a business combination within the allowed period would trigger liquidation, creating substantial doubt about Aimei’s ability to continue as a going concern.